Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 12, 2026.

Pariceract missed meeting the primary and key secondary efficacy end points in the phase 2b ACTIVATE trial, leading to the discontinuation of its development for GBA1-associated Parkinson disease.

Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.

The professor of psychiatry and neurology reviewed approaches to treating chorea, cognitive impairment, apathy, irritability, and aggression in Huntington disease, while highlighting the promise of huntingtin-lowering therapies.

The professor at MedStar Georgetown University Hospital spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]

Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.

At ATMRD 2026, the director of Movement Disorders at Banner Sun Health Research Institute discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.

Here's some of what is coming soon to NeurologyLive® this week.

Real-world survey data suggest deutetrabenazine treatment may be associated with improvements in patient- and caregiver-reported quality-of-life outcomes among individuals with Huntington disease chorea.

Exploratory post hoc data suggest prompt pimavanserin initiation within 6 to 12 months of PDP onset may yield a more favorable symptom trajectory, though prospective confirmation is needed.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

Joohi Jimenez-Shahed, MD, professor of neurology at Mount Sinai, commented on the evolving understanding of Tourette syndrome, persistent misconceptions, and emerging therapeutic and neuromodulation approaches for tic disorders.

Here's some of what is coming soon to NeurologyLive® this week.

Amlenetug, a monoclonal antibody targeting aggregated α-synuclein, showed a nonsignificant slowing of clinical progression compared with placebo and was generally well tolerated in patients with MSA.

A newly published analysis proposed a 4-point Tardive Dyskinesia Impact Scale (TDIS) threshold to interpret patient-reported improvement in patients living with tardive dyskinesia.

Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.

New phase 4 head-to-head data suggest Dysport may provide longer-lasting symptom control than Botox in adults with upper limb spasticity while maintaining comparable safety.

The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.

Here's some of what is coming soon to NeurologyLive® this week.

Kelsey Jensen, MD, a movement disorders neurologist at Allina Health, discussed Parkinson disease diagnosis, deep brain stimulation candidacy, treatment personalization, and ongoing unmet needs in PD care and research.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

James Beck, PhD, of the Parkinson’s Foundation, and Ben Casavant, PhD, of Tasso discuss new PD GENEration findings, the growing role of genetic testing in Parkinson disease, and how at-home blood collection may expand participation in neurologic research.